Recro and BioCorRx Expand Development and Manufacturing Relationship to Support BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
08. September 2021 07:00 ET
|
Recro Pharma, Inc.; BioCorRx, Inc.
SAN DIEGO and ANAHEIM, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex...
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
17. August 2021 07:00 ET
|
Recro Pharma, Inc.
Acquisition Expands Recro’s Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth Webcast...
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
13. August 2021 08:50 ET
|
Recro Pharma, Inc.
Combination of Synergistic Organizations Results in Broad CDMO Service with Capabilities Spanning from Pre-IND Development to Commercial Manufacturing and Packaging for Wide Range of Dosage Forms ...
IRISYS REDEYE-6A Pyroelectric Array Sensor Reverse Costing Analysis
22. Oktober 2013 09:54 ET
|
Research and Markets
Dublin, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/nfnv4z/irisys_redeye6a)
has announced the addition of the
"IRISYS REDEYE-6A Pyroelectric...